Treatment for Marijuana Abuse

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Vanderbilt University Medical Center, Nashville, TN
Marijuana Abuse+9 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections. This syndrome affects mostly women (~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant. Reduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID

Eligible Conditions

  • Marijuana Abuse
  • Coronavirus Disease 2019 (COVID‑19)
  • Syndrome
  • Long COVID

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Marijuana Abuse

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline to upto 180 mins

Baseline to upto 180 mins
IL-6 levels
Orthostatic Symptoms Score

Trial Safety

Safety Progress

1 of 3

Other trials for Marijuana Abuse

Trial Design

0 Treatment Group

60 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to upto 180 mins
Closest Location: Vanderbilt University Medical Center · Nashville, TN
Photo of vanderbilt university medical center 1Photo of vanderbilt university medical center 2Photo of vanderbilt university medical center 3
2006First Recorded Clinical Trial
1 TrialsResearching Marijuana Abuse
1026 CompletedClinical Trials

Who is running the clinical trial?

American Heart AssociationOTHER
280 Previous Clinical Trials
5,824,126 Total Patients Enrolled
Vanderbilt University Medical CenterLead Sponsor
758 Previous Clinical Trials
590,027 Total Patients Enrolled
Cyndya Shibao, M.DPrincipal InvestigatorVanderbilt University Medical Center
2 Previous Clinical Trials
100 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a confirmed COVID-19 infection.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.